Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

Join us for a webinar on how advances in target-based drug discovery are reshaping therapeutic design. We’ll explore innovations in structure-based design, computational modeling and validation that ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

Nimbus Therapeutics on Tuesday said that it has entered into a multi-year agreement with drugmaker Eli Lilly & Co to develop ...

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

KAIST (President Kwang Hyung Lee) announced on the 10th that a research team led by Professor Woo Youn Kim in the Department of Chemistry has developed an AI model named BInD (Bond and ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

An illustration of an algorithm predicting a protein structure, with digitized blocks on the left becoming ribbons on the right. An illustration of the RoseTTAFold software predicting a protein ...